Pancreatic metastasis from gastric carcinoma diagnosed by endoscopic ultrasound-guided fine-needle aspiration

Upper digestive endoscopy in a 36-year-old woman complaining of epigastric pain revealed an ulcerative lesion in the gastric body (Fig. 1a). Endoscopic biopsies confirmed a gastric adenocarcinoma (Fig. 1b, c). Endoscopic ultrasonography for cancer staging demonstrated a T2 gastric lesion, and a solid lesion measuring 10.2 mm × 9.6 mm in the pancreatic body (Fig. 2a). Histologic analysis of biopsy samples obtained by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA; Fig. 2b) showed neoplastic cells with the same histologic findings as those from the primary gastric cancer (Fig. 2c). Chest and abdominal computed tomography detected additional lung and liver metastases, but no pancreatic lesion was found. Palliative chemotherapy was planned for the patient.

Secondary involvement of the pancreas by systemic malignancies has been reported for up to 3% of solid pancreatic lesions [1], although in autopsy studies rates vary between 3% and 12% [2]. Renal carcinoma is the most common cancer to cause pancreatic metastases, followed by colorectal, lung, and breast carcinoma, as well as melanoma [3,4]. Hematogenic
gastric metastases are usually to the liver and the gut, although the lungs, adrenal glands, and bones can be affected. Pancreatic metastases of gastric cancer are extremely rare.

There are no radiological findings that are pathognomonic of pancreatic metastases [5]. Metastatic pancreatic involvement can manifest as a single mass, multifocal nodularity, or diffuse enlargement of the pancreas [2]. Where tumors occur in the pancreatic head, the main pancreatic duct and the common bile duct can be dilated, and in such cases the tumors are usually misdiagnosed as primary pancreatic malignancies [5]. Endoscopic ultrasound demonstrates a rounded, well-defined lesion with a homogeneous isoechoic or hypoechoic pattern [4]. Histologic confirmation of pancreatic tumors by means of EUS-FNA in patients with a previous or synchronous history of extrapancreatic malignancy is the best method for the diagnosis of pancreatic metastases (sensitivity 84% [3]), allowing appropriate clinical management to be started without the need for additional time-consuming diagnostic procedures.

**References**


**Corresponding author**

César Vivian Lopes, MD, PhD
Rua Prof. Cristiano Fischer 668/1001 C.E.P. 91
410-000 Porto Alegre-RS Brazil
Fax: +55-51-33388054
drcvlopes@gmail.com